Lantern Pharma launches ZetaOmics AI for cancer analysis
Lantern Pharma Inc. has launched ZetaOmics, an autonomous computational-biology module within its withZeta.ai platform designed for end-to-end bioinformatics and multi-omic analysis across all cancer types. The tool features fourteen embedded intelligence tools to prevent statistical pitfalls and is currently available via an early-access program to validate workflows before broader release.
*this image is generated using AI for illustrative purposes only.
Lantern Pharma Inc. has launched ZetaOmics, a computational-biology module within its withZeta.ai platform that functions as an autonomous "Computational Biologist." The new tool is designed to perform end-to-end bioinformatics and multi-omic analysis across any cancer type, with a specific focus on rare and pediatric cancers that often lack dedicated computational resources. By accessing a database of more than 615,000 curated cancer samples across eleven data sources, ZetaOmics aims to accelerate research by autonomously designing experiments and building rigorous cohorts in minutes rather than weeks.
First introduced as part of the withZeta.ai development roadmap unveiled on May 7, 2026, ZetaOmics is now entering an early-access program for select academic and industry bioinformatics teams as well as Lantern Pharma collaborators. This phased rollout is intended to validate the module against demanding research workflows and establish reference relationships ahead of broader commercial availability. The platform distinguishes itself by embedding domain intelligence directly into its tools, allowing it to reason about experimental design and prevent statistical pitfalls that can lead to false discoveries, rather than simply automating existing software routines.
Technical Capabilities
The ZetaOmics module incorporates fourteen distinct tools equipped with embedded domain intelligence to ensure rigorous analysis. These tools enable capabilities ranging from federated search across vast datasets to cohort building and survival modeling. The system is designed to recognize flaws in experimental design—such as incompatible data pipelines or confounding variables—and decline to run analyses that would produce invalid results, instead suggesting corrections.
| Module | What Sets It Apart | Autonomous Capability |
|---|---|---|
| Discovery | Ask in plain English | Federated search across 615K+ samples and 11 sources; auto-resolves cancer-type naming and routes only to datasets that hold the modality you need. |
| Gene Intelligence | Genome to proteome in one query | Links gene, transcript, and protein across Ensembl, UniProt, OMIM, and Orphanet, with pre-computed co-expression networks and rare-disease associations. |
| Batch Guardian | Stops false discoveries before they start | Profiles cohorts for hidden confounders and mixed pipelines before any analysis runs, and auto-matches anatomically correct normal controls. |
| Cohort Builder | Describe it; get an analysis-ready group or cluster | Turns plain-language filters into sample groups with diagnostic feedback — if a filter finds nothing, it returns the valid values that do exist. |
| Expression | The right normalization, chosen for you | Auto-selects normalization by task, scores curated biological signatures, resolves canonical pathways, and validates RNA against protein evidence. |
| Mutations | Not all variants are equal | Consequence-aware stratification (true loss-of-function vs. benign missense) and copy-number analysis with druggability context; live cBioPortal access. |
| Drug Response | The full statistical story | Resolves drug synonyms across ChEMBL/PubChem, checks data coverage before comparing, and reports effect size, confidence intervals, power, and FDR — not just p-values. |
| Differential Expression | Rigor enforced automatically | Adaptively selects edgeR, DESeq2, or limma-trend by sample size, refuses cross-pipeline and cross-specimen comparisons by default, and returns pathway enrichment with caveats surfaced. |
| Survival | Beyond a median split | Covariate-adjusted Cox modeling with hazard ratios, confidence intervals, and proportional-hazards diagnostics — flagging unadjusted associations as potentially confounded. |
| Stratification | Test any molecular hypothesis | Splits cohorts by expression, gene ratios, curated signatures, clinical metadata, or drug/CRISPR response into analysis-ready groups for downstream testing. |
| Protein Triage | Is the target actually druggable? | Ranks druggable, tumor-restricted targets against normal-tissue baselines — and for rare cancers with no prognostic panel, pivots automatically to plasma-based biomarker discovery. |
| Analysis Sandbox | Bespoke tests, no code required | Describe a custom analysis in plain language; the agent generates and runs sandboxed code against stored results, routing to guarded purpose-built tools whenever they apply. |
| Visualization | Publication-quality, every time | Thirteen presets (volcano, Kaplan-Meier, drug waterfall, dependency bars, concordance, PCA/UMAP and others) rendered deterministically so every figure matches the reported numbers. |
| Investigation Memory | Never rebuild from scratch | Stores, versions, and traces every result across turns, so complex multi-step workflows checkpoint their work and stack more analysis than any single run could survive. |
Strategic Implications
Panna Sharma, President and Chief Executive Officer of Lantern Pharma and Founder of withZeta.ai, stated that the platform encodes the judgment of expert bioinformaticians to make scientific rigor the default for researchers. The company expects ZetaOmics to drive value through three primary avenues: expanding into new markets by serving all cancer types, creating new collaboration and partnership opportunities through the early-access program, and generating new subscription revenue potential. The module is positioned to strengthen withZeta.ai as both a productivity engine for Lantern Pharma’s internal drug-discovery pipeline and a standalone commercial platform for the global oncology research community.
What specific metrics or milestones will Lantern Pharma use to evaluate the success of the early-access program before initiating broader commercial availability?
How will the integration of ZetaOmics into Lantern Pharma’s internal pipeline impact the company's projected R&D timelines and capital efficiency over the next 12 to 24 months?
Given the focus on rare and pediatric cancers, how does Lantern Pharma plan to address potential data sparsity challenges within the ZetaOmics database for these specific indications?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
